Key result
A systematic review suggests that coxibs should not be prescribed to patients with cardiovascular risk factors due to increased risks of myocardial infarction and stroke.
Why the study?
Do selective cyclooxygenase-2 inhibitors (coxibs) compared to conventional NSAIDs increase the risk of cardiovascular events in gastroenterological high-risk patients?
Population
Patients with chronic arthritis and one or more gastrointestinal risk factors, and patients with…
Comparison
Selective cyclooxygenase-2 inhibitors such as… vs Conventional non-steroidal anti-inflammatory…
Design
Systematic_review
Authors
Loading...
Avoid coxibs in patients with cardiovascular risk; reinforces preference for gastroprotected NSAIDs or acetaminophen in systematic evidence.
Systematic Review
Do selective cyclooxygenase-2 inhibitors (coxibs) compared to conventional NSAIDs increase the risk of cardiovascular events in gastroenterological high-risk patients?
Coxibs should be avoided in patients with cardiovascular risk factors due to increased risk of myocardial infarction and stroke; conventional NSAIDs with gastrointestinal protection or acetaminophen are preferred.
Nielsen et al. (2005) conducted a systematic review in Gastroenterological high-risk patients with chronic arthritis. Coxibs (selective cyclooxygenase-2 inhibitors) vs. Conventional non-steroidal anti-inflammatory drugs was evaluated. A systematic review suggests that coxibs should not be prescribed to patients with cardiovascular risk factors due to increased risks of myocardial infarction and stroke.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: